MTNB — Matinas BioPharma Holdings Share News
0.000.00%
Last trade - 00:00Brief: Matinas Biopharma Initiates EnACT Study Of MAT2203 For Treatment Of Fungal Cryptococcal Meningitis
Brief: Matinas Biopharma Receives Orphan Drug Designation From U.S. FDA For Mat2203
Brief: Matinas Biopharma Receives Orphan Drug Designation For Cryptococcosis treatment drug
Brief: Matinas Biopharma Holdings Q2 Loss Per Share $0.03
Matinas shares up as FDA awards meningitis drug "fast track" status
Brief: Matinas Biopharma Receives Qualified Infectious Disease Product And Fast Track Designations From U.S. FDA For Mat2203
Matinas BioPharma rises on research pact with ViiV Healthcare
Brief: Matinas Biopharma Announces A Research Collaboration With ViiV Healthcare
Brief: Matinas Biopharma Holdings Reports Q1 Loss Per Share Of $0.04
Matinas BioPharma: Drops on $30 mln equity raise
Brief: Matinas Biopharma Says Public Offering Of 27.3 Mln Common Shares Priced At $1.10 Per Share
Matinas BioPharma: Drops on stock offering plans
Brief: Matinas Biopharma Anticipates Using Net Proceeds For Ongoing Development Activities For Its Product Candidates, Among Others
Brief: Matinas Biopharma Says Keith Kucinski Appointed CFO
Brief: Matinas Biopharma QTRLY Loss Per Share $ 0.03
Brief: Matinas Biopharma Reports Q2 Loss Per Share $0.40
Brief: NIH And Matinas Biopharma Announce Research Collaboration
Brief: Matinas Biopharma Announces Pricing Of $8 Mln Public Offering
Brief: Matinas Biopharma Holdings Reports Q1 Loss Per Share Of $0.05